Millipore Sigma Vibrant Logo

407240 Insulin-Like Growth Factor-I, Human, Recombinant, E. coli

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: rhIGF-I, Somatomedin-C

407240
  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Purity
      ≥97% by SDS-PAGE
      Description
      Overview

      This product has been discontinued.





      Recombinant, human insulin-like growth factor-I (70 amino acids) expressed in E. coli. Has about 40% homology to insulin and produces metabolic effects similar to insulin. Acts as an important local regulator of bone formation. Increases bone formation and bone resorption. Also inhibits etoposide-induced apoptosis in BALB/c 3T3 cells. Stimulates the activity of protein tyrosine kinases in both normal and diethylstilbestrol-treated hamster kidneys. Primarily involved in response of cells to growth hormones.
      Catalogue Number407240
      Brand Family Calbiochem®
      SynonymsrhIGF-I, Somatomedin-C
      References
      ReferencesStabnov, L., et al. 2002. Bone 30, 909.
      Devireddy, L.R., et al. 2001. Science 293, 829.
      Chen, C.W., and Ray, D. 1995. Carcinogenesis 16, 1339.
      Sell, C., et al. 1995. Cancer Res. 55, 303.
      Amarani, S., et al. 1993. J. Bone Min. Res. 8, 157.
      Mohan, S. 1993. Growth Regul. 3, 67.
      Lowe, W.L. 1991. In Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., ed.) CRC Press Inc. Boca Raton, FL. p. 49.
      Rudd, B.T. 1991. Ann. Clin. Biochem. 28, 542.
      Schofield, P.N. 1991. Acta Paediatr. Scand. 372, 83.
      Werner, H., et al. 1991. In Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Raizada, M.K., and LeRoith, D., eds.) Plenum, NY. p. 263.
      Humbel, R.E. 1984. In Hormonal Proteins and Peptides (Jin Li, C.H., ed.) Academic, NY. Vol. 12, p. 57.
      Product Information
      CAS number67763-96-6
      FormLyophilized
      Applications
      Biological Information
      Biological activityED₅₀ = 0.3-1.5 ng/ml as measured in a cell proliferation assay with MCF-7 human breast carcinoma cells.
      Purity≥97% by SDS-PAGE
      Physicochemical Information
      ContaminantsEndotoxin: ≤1 EU/µg IGF-I
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSNM8905000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 3 months at -70°C. Dilute with buffer to desired pH just prior to use.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      407240 0

      Documentation

      Insulin-Like Growth Factor-I, Human, Recombinant, E. coli FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Insulin-Like Growth Factor-I, Human, Recombinant, E. coli Certificats d'analyse

      TitreNuméro de lot
      407240

      Références bibliographiques

      Aperçu de la référence bibliographique
      Stabnov, L., et al. 2002. Bone 30, 909.
      Devireddy, L.R., et al. 2001. Science 293, 829.
      Chen, C.W., and Ray, D. 1995. Carcinogenesis 16, 1339.
      Sell, C., et al. 1995. Cancer Res. 55, 303.
      Amarani, S., et al. 1993. J. Bone Min. Res. 8, 157.
      Mohan, S. 1993. Growth Regul. 3, 67.
      Lowe, W.L. 1991. In Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., ed.) CRC Press Inc. Boca Raton, FL. p. 49.
      Rudd, B.T. 1991. Ann. Clin. Biochem. 28, 542.
      Schofield, P.N. 1991. Acta Paediatr. Scand. 372, 83.
      Werner, H., et al. 1991. In Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Raizada, M.K., and LeRoith, D., eds.) Plenum, NY. p. 263.
      Humbel, R.E. 1984. In Hormonal Proteins and Peptides (Jin Li, C.H., ed.) Academic, NY. Vol. 12, p. 57.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision31-March-2008 JSW
      SynonymsrhIGF-I, Somatomedin-C
      DescriptionRecombinant, human insulin-like growth factor-I (70 amino acids) expressed in E. coli. Growth-promoting, single-chain polypeptide hormone that is structurally, functionally, and genetically related to insulin. Has about 40% homology to insulin and produces metabolic effects similar to insulin. Functionally, the IGFs share three activities with insulin: demonstrate insulin-like metabolic activity, induce sulfate uptake into cartilage proteoglycans, and induce mitotic activity in selected cell lines. Acts as an important local regulator of bone formation. Also inhibits etoposide-induced apoptosis in BALB/c 3T3 cells.
      FormLyophilized
      CAS number67763-96-6
      RTECSNM8905000
      Purity≥97% by SDS-PAGE
      ContaminantsEndotoxin: ≤1 EU/µg IGF-I
      Biological activityED₅₀ = 0.3-1.5 ng/ml as measured in a cell proliferation assay with MCF-7 human breast carcinoma cells.
      SolubilityReconstitute to ≥0.1 mg/ml with sterile PBS containing 0.1% BSA or HSA.
      Storage ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 3 months at -70°C. Dilute with buffer to desired pH just prior to use.
      Toxicity Standard Handling
      Merck USA index14, 4986
      ReferencesStabnov, L., et al. 2002. Bone 30, 909.
      Devireddy, L.R., et al. 2001. Science 293, 829.
      Chen, C.W., and Ray, D. 1995. Carcinogenesis 16, 1339.
      Sell, C., et al. 1995. Cancer Res. 55, 303.
      Amarani, S., et al. 1993. J. Bone Min. Res. 8, 157.
      Mohan, S. 1993. Growth Regul. 3, 67.
      Lowe, W.L. 1991. In Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., ed.) CRC Press Inc. Boca Raton, FL. p. 49.
      Rudd, B.T. 1991. Ann. Clin. Biochem. 28, 542.
      Schofield, P.N. 1991. Acta Paediatr. Scand. 372, 83.
      Werner, H., et al. 1991. In Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Raizada, M.K., and LeRoith, D., eds.) Plenum, NY. p. 263.
      Humbel, R.E. 1984. In Hormonal Proteins and Peptides (Jin Li, C.H., ed.) Academic, NY. Vol. 12, p. 57.

      Produits & Applications associés

      Related Products

      Référence Description  
      407245 Insulin-Like Growth Factor-II, Human, Recombinant, E. coli Prix & Disponibilité

      Catégories

      Life Science Research > Proteins and Enzymes > Cytokines & Growth Factors
      Life Science Research > Cell Culture and Systems > Cell Culture Media and Supplements > Cell Culture Supplements > Cytokines & Growth Factors